Categories Uncategorized

Lumenate App Takes Users on a Trip, Sans Psychedelics

Psychedelics went mainstream a few years ago, and with research on these substances and their therapeutic benefits still ongoing, various jurisdictions across the United States have been considering whether to legalize or decriminalize magic mushrooms as well as other entheogenic fungi and plants. Additionally, more companies are developing psychedelic compounds as consumer products or medications in a bid to profit from the incoming regulatory environment.

One of these is Lumenate, a company founded by Jay Conlon and Tom Galea. The two inventors have devised a way to induce a semi-psychedelic state using a device that can be found everywhere in the society today: a smartphone. The two inventors have developed the Lumenate app, which uses a smartphone’s flashlight to create a stroboscopic light sequence that helps guide the user neurologically into an altered state of consciousness, between classic psychedelics and deep meditation. The app was launched recently on both Google Play and Apple App store.

The two inventors met while they were studying engineering at the University of Liverpool. After graduating, the two decided to help individuals around the world live fulfilling and freer lives. They interviewed hundreds of individuals from across the globe in a bid to understand the concept of fulfilment better. While researching on how subconscious exploration could assist in inspiration, the two discovered that the current methods of exploring the subconscious, which included emerging psychedelic therapy and years of mediation training, had considerable barriers to accessibility.

This is what led them to develop a research-based method that utilises sound and light to guide the user’s brain into the desired state.

In an interview, Conlon explained that light being flashed in a particular way caused neurons in the brain to fire and react in a synchronised rhythm that safely helped guide the brain into a semi-psychedelic, deeply meditative state of consciousness. This results in an effortless and instant way to explore the subconscious.

The UK-wide lockdown that was imposed at the height of the pandemic led the entrepreneurs to develop the Lumenate experience into a smartphone application. Conlon reported that participants who used the app admitted that they were inspired to make changes in their lives and find new solutions to creative challenges.

A trial version of the application is available for free download on the aforementioned stores. Users who find value in the experience can upgrade to the full version of the app, which will unlock a catalog of sessions that suit various time frames and moods.

While the Lumanate app may suffice for some users, plenty of patients will need medicines made from psychedelic substances in order to see relief from their symptoms. Companies such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are making every effort to quickly develop and commercialize psychedelic medicines so that mental and other health conditions can be treated.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

1 day ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 months ago